Klopidogrel direncine farmakogenetik yaklaşım: iki erkek kardeşde tekrarlayan stent trombozisi olgusu

Abstract

Klopidogrel, koroner stent implantasyonundan sonra tromboz gelişiminin önlenmesi için günümüzde tercih edilen ilaçlardan (prasugrel ve ticagrelor) biridir. Bununla birlikte bir çok hastada stent trombozisi gelişmeye devam etmektedir. Tekrarlayan iskemik komplikasyonların nedeninin yetersiz klopidogrel yanıtından kaynaklandığını gösteren çalışmaların sayısı gün geçtikçe artmaktadır. Yetersiz klopidogrel yanıtına neden olan mekanizmaların tartışılması kayda değerdir. Bu olgu sunumunda olası klopidogrel direnci ile birlikte tekrarlayan stent trombozisi bulunan hastada tıbbi literatür desteği ile klopidogrel direncinin mekanizmaları tartışılacaktır.

Keywords

• klopidogrel
• stent
• trombozis

Pharmacogenetic approach to clopidogrel resistance: recurrent stent thrombosis in two brother

Abstract

Clopidogrel, is the antiplatelet treatment choice for prevention of thrombosis after coronary stent implantation.However, despite the use of clopidogrel, a considerable number of patients continue to have stent thrombosis.There is a growing degree of evidence that recurrence of ischemic complications may be attributed to poorresponse of clopidogrel. It is noteworthy to elucidate the mechanisms leading to poor clopidogrel effects.We reportrecurrent stent thrombosiswith possible clopidogrel resistanceand aimed to discuss the mechanismsof clopidogrel resistance in the light of the medical literature

Keywords

• clopidogrel
• stents
• thrombosis

References

1. Matezky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109 (25): 3171-3175.
2. Kim JY, Yoon JH. Aspirin and clopidogrel resistance in drug eluting stent era. Korean Circ J 2007; 37(4): 135-147.
3. Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am CollCardiol 2006; 48 (9): 1742-1750.
4. Müller I, Seyfarth M, Rudiger S, Wolf B, Pogatsa- Murray G, Schömig A, et al. Effects of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001;85(1):92-93.
5. Kastrati A, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, Ten Berg JM. A clinical trial of abximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Eng J Med 2004;350(3):232-238.
6. Qureshi Z, Hobson AR. Clopidogrel resistance: Where are we now? CardiovascTher. doi: 10.1111/j.1755- 5922.2011.00296.x
7. Campo G, Fileti L, Valgimigli M, Tebaldi M, Cangiano E, Cavazza C, Marchesini K, Ferrari R. Poor response to clopidogrel: current and future options for its management. J Thromb Thrombolysis 2010;30(3): 319-331
8. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid N.A, Okazaki O, et al. Identification of thehumancytochrome P450 enzymesinvolved in thetwooxidativesteps inthebioactivation of clopidogreltoitspharmacologicallyactivemetabolite. DrugMetabDispos 2010;38(1):92- 99.

9. Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug- drug interaction. Circulation 2003;107(1):32-37.
10. Malström RE, Östergren J, Jorgensen L, Hjemdahl P. Influence of statin treatment on platelet inhibition by clopidogrel, a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment. J Int Med 2009;266(5):457-466.
11. Riondino S, Petrini N, Donato L, Torromeo C, Tanzilli G, Pulcinelli FM, Barilla F. Effects of rosuvastatin on platelet inhibition by clopidogrel in cardiovascular patients. J Thromb Thrombolysis 2009;28(2):151-155
12. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytochrome P4502C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373(9660):309-317.
13. Silvano M, Zambon CF, De Rosa G, Plebani M, Pengo V, Napodano M, Padrini R. A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty. J Thromb Thrombolysis 2011;31(2);233- 234.
14. Dahl ML, Gunes A. Implications of Inter-Individual differences in clopidogrel metabolism, with focus on pharmacogenetics. Pharmaceuticals 2010;3(4):782- 794.
15. Faraday N, Yanek LR, Yang XP, Mathias R, Herrera- Galeano JE, Suktitipat B, et al. Identification of a specific intronic PEAR1 gene variant associated with greater platelet aggregability and protein expression. Blood 2011;118(12):3367-3375.
16. Goodall AH, Burns P, Salles I, Macaulay IC, Jones CI, Ardissino D, et al. Transcription profiling in human platelets reveals LRRFIP1 as a novel protein regulating platelet function. Blood 2011;116(22):4646-4656.
17. Angelillo-Scherrer A, Fontana P, Burnier L, Roth I, Sugamele R, Brisset A, et al. Connexin37 limits thrombus propensity by downregulating platelet reactivity. Circulation 2011;124(8):930-939.
18. Bouman HJ, Schömig E, Werkum JW, Velder J, Hackeng CM, Hischhauser C, et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat Med 2011;17(1):110-116.